Who's got the edge in the hot PCSK9 case after court arguments? Amgen has an 80% shot, one analyst said. Nope, Regeneron and Sanofi, says another.

AstraZeneca will sell rights to its migraine treatment Zomig for all markets outside of Japan to Germany’s Grünenthal for up to $302 million.

Last summer’s most ballyhooed M&A deal—Pfizer’s $14 billion buyout of Medivation—doesn’t look so impressive anymore, thanks to data rolled out at ASCO.

Pfizer has raised the U.S. prices on 91 medicines by an average of 20% so far this year.

Alexion’s CEO has brought in more new people, including more former Baxalta colleagues, after his executive clean sweep last week.

Some powerful institutional investors are steamed about Mylan Chairman Robert Coury’s $97 million in compensation, and they want him voted out.

Novartis said that its Sandoz unit will succumb to the pricing pressure that burned the revenues of most generics makers in the first quarter.

With gaping holes in its portfolio, some analysts worry that Novartis CEO Joe Jimenez might take cash from expected asset sales to do a megadeal.